drugset / Trial / NCT03742986
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Timeline
- Start
- 2019-05-02
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |